Heat-shock protein vaccines as active immunotherapy against human gliomas

References

• Yang I, Kremen TJ, Giovannone AJ et al. Modulation of major histocompatibility complex class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-α and interferon-γ treatment of human glioblastoma multiforme. J. Neurosurg.100(2), 310–319 (2004).
   PubMed Web of Science ®Google Scholar
• Park HG, Han SI, Oh SY, Kang HS. Cellular responses to mild heat stress. Cell. Mol. Life Sci.62(1), 10–23 (2005).
   PubMed Web of Science ®Google Scholar
• Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol.5(10), 781–791 (2004).
   PubMed Web of Science ®Google Scholar
• Soo ET, Yip GW, Lwin ZM, Kumar SD, Bay BH. Heat shock proteins as novel therapeutic targets in cancer. In Vivo22(3), 311–315 (2008).
   PubMed Web of Science ®Google Scholar
• Pockley AG. Heat shock proteins as regulators of the immune response. Lancet362(9382), 469–476 (2003).
   PubMed Web of Science ®Google Scholar
• Voellmy R. Feedback regulation of the heat shock response. Handb. Exp. Pharmacol.(172), 43–68 (2006).
   PubMedGoogle Scholar
• Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol.81(1), 15–27 (2007).
   PubMed Web of Science ®Google Scholar
• Srivastava PK. Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv. Cancer Res.62, 153–177 (1993).
   PubMed Web of Science ®Google Scholar
• Manjili MH, Wang XY, Park J, Facciponte JG, Repasky EA, Subjeck JR. Immunotherapy of cancer using heat shock proteins. Front. Biosci.7, d43–d52 (2002).
   PubMed Web of Science ®Google Scholar
• Subjeck JR, Shyy TT. Stress protein systems of mammalian cells. Am. J. Physiol.250(1 Pt 1), C1–17 (1986).
   PubMed Web of Science ®Google Scholar
• Binder RJ. Heat shock protein vaccines: from bench to bedside. Int. Rev. Immunol.25(5–6), 353–375 (2006).
   PubMed Web of Science ®Google Scholar
• Srivastava PK, Amato RJ. Heat shock proteins: the ‘swiss army knife’ vaccines against cancers and infectious agents. Vaccine19(17–19), 2590–2597 (2001).
   PubMed Web of Science ®Google Scholar
• Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science269(5230), 1585–1588 (1995).
   PubMed Web of Science ®Google Scholar
• Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science278(5335), 117–120 (1997).
   PubMed Web of Science ®Google Scholar
• Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins Gp96, HSP90, and HSP70. J. Immunol.152(11), 5398–5403 (1994).
   PubMed Web of Science ®Google Scholar
• Srivastava PK, Deleo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl Acad. Sci. USA83(10), 3407–3411 (1986).
   PubMed Web of Science ®Google Scholar
• Srivastava PK, Menoret A, Basu S, Binder RJ, Mcquade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity8(6), 657–665 (1998).
   PubMed Web of Science ®Google Scholar
• Blachere NE, Li Z, Chandawarkar RY et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med.186(8), 1315–1322 (1997).
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Srivastava PK. Heat shock protein–peptide complexes as immunotherapy for human cancer. Mol. Med. Today4(11), 478–484 (1998).
   PubMedGoogle Scholar
• Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J. Biol. Chem.276(20), 17163–17171 (2001).
   PubMed Web of Science ®Google Scholar
• Castelli C, Rivoltini L, Rini F et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol. Immunother.53(3), 227–233 (2004).
   PubMed Web of Science ®Google Scholar
• Nicchitta CV, Carrick DM, Baker-Lepain JC. The messenger and the message: Gp96 (grp94)-peptide interactions in cellular immunity. Cell Stress Chaperones9(4), 325–331 (2004).
   PubMed Web of Science ®Google Scholar
• Wang XY, Li Y, Yang G, Subjeck JR. Current ideas about applications of heat shock proteins in vaccine design and immunotherapy. Int. J. Hyperthermia21(8), 717–722 (2005).
   PubMed Web of Science ®Google Scholar
• Grossmann ME, Madden BJ, Gao F et al. Proteomics shows HSP70 does not bind peptide sequences indiscriminately in vivo. Exp. Cell Res.297(1), 108–117 (2004).
   PubMed Web of Science ®Google Scholar
• Singh-Jasuja H, Hilf N, Arnold-Schild D, Schild H. The role of heat shock proteins and their receptors in the activation of the immune system. Biol. Chem.382(4), 629–636 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhao X, Burkholder WF et al. Structural analysis of substrate binding by the molecular chaperone dnak. Science272(5268), 1606–1614 (1996).
   PubMed Web of Science ®Google Scholar
• Graner MW, Bigner DD. Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol.7(3), 260–278 (2005).
   PubMed Web of Science ®Google Scholar
• Scheibel T, Weikl T, Buchner J. Two chaperone sites in HSP90 differing in substrate specificity and ATP dependence. Proc. Natl Acad. Sci. USA95(4), 1495–1499 (1998).
   PubMed Web of Science ®Google Scholar
• Workman P. Altered states: selectively drugging the HSP90 cancer chaperone. Trends Mol. Med.10(2), 47–51 (2004).
   PubMed Web of Science ®Google Scholar
• Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU. In vivo function of HSP90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol.143(4), 901–910 (1998).
   PubMed Web of Science ®Google Scholar
• Wang XY, Kaneko Y, Repasky E, Subjeck JR. Heat shock proteins and cancer immunotherapy. Immunol. Invest.29(2), 131–137 (2000).
   PubMedGoogle Scholar
• Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and ctl priming. Immunogenetics39(2), 93–98 (1994).
   PubMed Web of Science ®Google Scholar
• Roigas J, Wallen ES, Loening SA, Moseley PL. Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. Adv. Exp. Med. Biol.451, 225–229 (1998).
   PubMed Web of Science ®Google Scholar
• Arnold-Schild D, Hanau D, Spehner D et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol.162(7), 3757–3760 (1999).
   PubMed Web of Science ®Google Scholar
• Basu S, Binder RJ, Ramalingam T, Srivastava PK. Cd91 is a common receptor for heat shock proteins Gp96, HSP90, HSP70, and calreticulin. Immunity14(3), 303–313 (2001).
   PubMed Web of Science ®Google Scholar
• Binder RJ, Han DK, Srivastava PK. Cd91: a receptor for heat shock protein Gp96. Nat. Immunol.1(2), 151–155 (2000).
   PubMed Web of Science ®Google Scholar
• Binder RJ, Karimeddini D, Srivastava PK. Adjuvanticity of α 2-macroglobulin, an independent ligand for the heat shock protein receptor Cd91. J. Immunol.166(8), 4968–4972 (2001).
   PubMed Web of Science ®Google Scholar
• Binder RJ, Srivastava PK. Essential role of Cd91 in re-presentation of Gp96-chaperoned peptides. Proc. Natl Acad. Sci. USA101(16), 6128–6133 (2004).
   PubMed Web of Science ®Google Scholar
• Delneste Y, Magistrelli G, Gauchat J et al. Involvement of Lox-1 in dendritic cell-mediated antigen cross-presentation. Immunity17(3), 353–362 (2002).
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Takemoto S, Takakura Y. Heat shock protein derivatives for delivery of antigens to antigen presenting cells. Int. J. Pharm.354(1–2), 23–27 (2008).
   PubMed Web of Science ®Google Scholar
• Castellino F, Boucher PE, Eichelberg K et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med.191(11), 1957–1964 (2000).
   PubMed Web of Science ®Google Scholar
• Takakura Y, Takemoto S, Nishikawa M. HSP-based tumor vaccines: state-of-the-art and future directions. Curr. Opin. Mol. Ther.9(4), 385–391 (2007).
   PubMedGoogle Scholar
• Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol.12(11), 1539–1546 (2000).
   PubMed Web of Science ®Google Scholar
• Wang HH, Mao CY, Teng LS, Cao J. Recent advances in heat shock protein-based cancer vaccines. Hepatobiliary Pancreat. Dis. Int.5(1), 22–27 (2006).
   PubMedGoogle Scholar
• Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci.31(3), 164–172 (2006).
   PubMed Web of Science ®Google Scholar
• Calderwood SK, Theriault JR, Gong J. Message in a bottle: role of the 70 kDa heat shock protein family in antitumor immunity. Eur J. Immunol.35(9), 2518–2527 (2005).
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones10(2), 86–103 (2005).
   PubMed Web of Science ®Google Scholar